International Summit on Psychedelic Therapies for Mental Illness: 17-20 November 2021 - Online Event

Mind Medicine Australia will hold a two-day International Summit on Psychedelic Therapies for Mental Illness in November 2021. Find out more: https://www.summit.mindmedicineaustralia.org/

It will bring together clinicians, scientists, academics, mental and public health professionals, philanthropists, investors, Government, law and policy leaders, business, industry, insurers, consumers and other interested stakeholders.

The event will also feature a two-day pre-Summit Introductory Workshop Program (17-18
November) led by Nigel Denning, Dr Tra-ill Dowie with world-leading therapist trainer Dr
Bill Richards (USA) from Johns Hopkins University. It is for anyone with an interest in the
topic and who is considering further development of their current therapeutic skills or who
are eager to gain a detailed understanding of psychedelic-assisted psychotherapy for the
treatment of mental illness.

The program features a world class line-up of talks, workshops, hot spots, panel conversations and creative moments.

Leading international speakers confirmed for the 2-day summit and Mind Medicine Australia
Ambassadors include: Professor David Nutt (UK) Head of Neuropsychopharmacology at
Imperial College London and lead advisor on psilocybin assisted therapy for treatment-resistant depression, Dr Gabor Maté (Canada) renowned trauma and addiction physician, Professor Roland Griffiths (USA) Professor in the Departments of Psychiatry and Neurosciences at the Johns Hopkins University School of Medicine, Johann Hari (UK) journalist and bestselling author, Dr Bill Richards (USA) world-leading therapist trainer and psychologist at the Johns Hopkins School of Medicine, Dr Ben Sessa (UK) psychiatrist, researcher and writer and currently leading the Imperial College trials on using MDMA therapy for alcohol dependence, Dr Robin Carhart-Harris (UK) Head of the Centre for Psychedelic Research at Imperial College London, Francoise Bourzat (USA) Counsellor and Author, Wade Davis (Canada) anthropologist, ethnobotanist and Explorer in Residence at the National Geographic Society, Dr Alberto Villoldo (USA) medical anthropologist and author, Dr Lynn Marie Morski (USA) President of the Psychedelic Medicine Association, Matthew Johnson (USA) Professor of Psychiatry and Behavioural Sciences at Johns Hopkins University School of Medicine with a focus on psychedelic research for the treatment of mental illness, Dr Adele Lafrance (USA/Canada) Clinical Psychologist and Research Scientist, Patrycja Slawuta (USA) Researcher & Psychologist, Dr Gabby Agin- Liebes (USA) Psilocybin researcher at Weill Institute for Neuroscience, Admiral Chris Barrie AC (AUS) former Head of the Australian Defence Force and Strategic Leadership Consultant, Arthur Christopoulos (AUS) Professor of Analytical Pharmacology and Molecular Neuropsychopharmacologist at Monash University, Dr Reid Robinson (USA) psychedelic psychiatrist, Dr Jennifer Mitchell (USA) Professor in the Departments of Neurology and Psychiatry and Behavioral Sciences at UCSF, Ronan Levy (Canada) Co-founder and the Executive Chairman of Field Trip Health, Srinivas Rao (USA) co-founder & Chief Scientific Officer, atai Life Sciences, Kelsey Ramsden (Canada) Co-Founder, CEO & President of Mindcure, Dr Lyle Oberg (Canada) Co-Founder and CEO at MYND, Michael Winlo (AUS) Managing Director, Emyria, John Skerritt (AUS) Deputy Secretary, Health Products Regulation Group - TGA, Dr Simon Longstaff (AUS) Executive Director of The Ethics Centre, Dr Eli Kotler (AUS) Psychiatrist and Director of Medicine at Malvern Private Hospital… and more to be announced.

Key themes will include:
• The current state of mental health in Australia, existing treatments and the need for innovation
• The Science of Psychedelics: Therapeutic mechanisms and clinical outcomes for a range of mental illnesses and other conditions
• Indigenous Wisdom and expanded states of consciousness for healing and growth Depression, Trauma, Addiction and Suicide: Prevention is better than cure
• Living until you die: the promise of psilocybin-assisted therapy for end-of-life
• The way forwards for Australia: Ethical, legal, and implementation frameworks for psychedelic treatments and a new paradigm for treatment of mental illness
• Creating the Future: What the Psychedelic Industry Will Look Like 5 Years Out?

Psychedelic therapies have been granted Breakthrough Therapy status by the FDA in the
USA due to current promising research in the treatment of depression and PTSD. We look
forward to collaborating with you to explore psychedelic treatment options to help address
the mental health epidemic we currently face, and offer treatments to those who need it
most.

Together we can change the treatment paradigm and create a healthier, happier future.
For more details and to register for tickets, please visit:
https://summit.mindmedicineaustralia.org/